- •Redefining the nine hole peg test in progressive MS makes it a more useful outcome.
- •Non-ambulatory MS patients continue to experience nine hole peg test worsening.
- •Our findings suggest that non-ambulatory people with MS can be included in clinical trials.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Disability as an outcome in MS clinical trials.Neurology. 2008; 71: 624-631https://doi.org/10.1212/01.wnl.0000313034.46883.16
- The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.Mult. Scler. 2017; 23: 711-720https://doi.org/10.1177/1352458517690824
- Multiple Sclerosis Functional Composite (MSFC): Administration and Scoring Manual.National Multiple Sclerosis Society, New York2001
- The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.Mult. Scler. 2004; 10: 55-60
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.Lancet Neurol. 2018; 17: 405-415https://doi.org/10.1016/S1474-4422(18)30069-3
- Comparative utility of disability progression measures in PPMS Analysis of the PROMiSe data set.Neurol Neuroimmunol. Neuroinflamm. 2017; 4: e358https://doi.org/10.1212/NXI.0000000000000358
- Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.Neurology. 2021; 96: e111-e120https://doi.org/10.1212/WNL.0000000000011123
- Clinical outcome measures in SPMS trials: an analysis of the IMPACT and ASCEND original trial data sets.Mult. Scler. 2020; 26: 1540-1549https://doi.org/10.1177/1352458519876701
- A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.Mult. Scler. 2021; 27: 1864-1874https://doi.org/10.1177/1352458520987539
- Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.Mult. Scler. 2006; 12: 594-598
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.Mult. Scler. 2017; 23: 704-710https://doi.org/10.1177/1352458517690823
- Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.Neurology. 2005; 64: 1144-1151https://doi.org/10.1212/01.WNL.0000156155.19270.F8
- Quantitative functional measures in MS: what is a reliable change?.Neurology. 2002; 58: 1294-1296
- Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis.Mult. Scler. Relat. Disord. 2019; 30: 1-8https://doi.org/10.1016/j.msard.2019.01.043
- Nine Hole Peg Test asymmetry in refining upper limb assessment in multiple sclerosis.Mult. Scler. Relat. Disord. 2020; 45102422https://doi.org/10.1016/j.msard.2020.102422
- Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.Ann. Neurol. 2007; 61: 14-24https://doi.org/10.1002/ana.21079